Recent News

DefiniGEN / Fri, Sep 27, 2024
DefiniGEN secures ISO 9001:2015 recertification

Upcoming Events

BIO-Europe 2024
4-6 November 2024 / Stockholm, Sweden

 

Enabling cures for liver disease through highly predictive in vitro modeling

We generate high-quality, phenotypically relevant disease modeled hepatocytes that can be utilized to screen compounds.

Disease Modeling

DefiniGEN's platform technology enables the generation of predictive and phenotypically relevant iPSC-derived human disease models for a wide range of metabolic and liver diseases which can be produced at scale.

Learn more >

+
disease-modelling-image

Profiling Molecules

Combine our expertise at generating iPSC-derived hepatocyte disease models with our wide panel of bespoke bioassays. We work as partners with your team to design and implement in-house screening of small molecules and advanced genetic therapies, so you can advance your program at speed.

Learn more >

+
phenotypic-screening-image

Specialist CRO focused on delivering liver and metabolic disease models

icons_dark blue2
Highly Predictive

Opti-HEPs successfully recapitulate key aspects of disease pathophysiology across a wide-range of conditions that affect different aspects of liver function.

icons_dark blue3
Scalable

 

DefiniGEN’s proprietary differentiation protocol permits large-scale generation of hepatocyte-like cells with field leading purity and functionality.

icons_dark blue
Optimized Bioassay Development

Optimized bioassays that can accurately evaluate compound potency, efficacy and delivery.

Scientific expertise

definigen-logo-background-overlay
Advance your scientific discoveries with our tailored disease modeling products and services.